Drug Trial News

RSS

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.

5 Oct 2012

Mexiletine improves patient-reported stiffness in nondystrophic myotonia

An older medication originally approved to treat heart problems eases the symptoms of a very rare muscle disease that often leaves its sufferers stiff and in a good deal of pain, physicians and researchers report in the Oct. 3 issue of the Journal of the American Medical Association.

4 Oct 2012

Penn researchers to begin Microbion's BisEDT gel Phase 2 trials in post-surgical orthopedic infections

A team of researchers led by Samir Mehta, MD, chief of the Orthopaedic Trauma & Fracture Service at the Perelman School of Medicine at the University of Pennsylvania, has received a $2.5 million grant from the Congressionally Directed Medical Research Program (CDMRP), provided through the U.S. Department of Defense (DoD), to begin Phase 2 human trials of a study that examines the effective treatment of post-surgical orthopedic infections using Microbion Corporation's topical BisEDT drug.

4 Oct 2012

Circassia commences ToleroMune phase 3 trial in cat allergen-induced rhinoconjunctivitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune cat allergy treatment for cat allergen-induced rhinoconjunctivitis.

4 Oct 2012

Estrogen/progesterone treatment started soon after menopause appears safe and effective

Estrogen/progesterone treatment started soon after menopause appears safe and relieves many of the symptoms menopausal women face as well as improving mood and markers of cardiovascular risk, according to a multicenter randomized study presented at the North American Menopause Society (NAMS) Annual Meeting in Orlando, Florida.

4 Oct 2012

Positive data from three Onconova Ex-RAD clinical trials on acute radiation syndrome

Onconova Therapeutics, Inc. today announced positive human safety, tolerability, and pharmacokinetic data from three clinical trials of Ex-RAD (recilisib sodium, ON 01210.Na), a novel radioprotectant being developed as a medical countermeasure for the treatment of acute radiation syndrome (ARS).

4 Oct 2012

Merck announces data from MK-3102 Phase IIb trial on type 2 diabetes

Merck, known as MSD outside the United States and Canada, today announced Phase IIb data for MK-3102, the company's investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes.

4 Oct 2012

Vitamin D3 intake does not reduce incidence or severity of upper respiratory tract infections

Although some data have suggested a possible inverse association between serum vitamin D levels and the incidence of upper respiratory tract infections (colds), participants in a randomized controlled trial who received a monthly dose of 100,000 IUs of vitamin D3 did not have a significantly reduced incidence or severity of colds, according to a study in the October 3 issue of JAMA.

4 Oct 2012

Mexiletine use improves stiffness in patients with nondystrophic myotonias

Preliminary research finds that for patients with nondystrophic myotonias (NDMs), rare diseases that affect the skeletal muscle and cause functionally limiting stiffness and pain, use of the anti-arrhythmic medication mexiletine resulted in improvement in patient-reported stiffness, according to a preliminary study in the October 3 issue of JAMA.

3 Oct 2012

Boehringer Ingelheim, Lilly announce data from LY2605541 Phase II study on type 2 diabetes

Eli Lilly and Company and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes.

3 Oct 2012

Positive results from Noven’s LDMP Phase 3 clinical studies on menopausal VMS

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced positive results from two multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical studies evaluating low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

3 Oct 2012

Biomarkers can increase success rate of clinical trials for breast cancer drugs by almost 50%

Using biological markers--genetic characteristics that are associated with some patients with breast cancer--can increase the success rate of clinical trials for breast cancer drugs by almost 50 per cent, says new research from the University of Toronto Mississauga.

3 Oct 2012

Omega-3 fatty acid supplements could slow key biological process linked to aging

Taking enough omega-3 fatty acid supplements to change the balance of oils in the diet could slow a key biological process linked to aging, new research suggests.

2 Oct 2012

Novel therapy shows promise in treating multiple myeloma following stem cell transplants

A novel therapy in the early stages of development at Virginia Commonwealth University Massey Cancer Center shows promise in providing lasting protection against the progression of multiple myeloma following a stem cell transplant by making the cancer cells easier targets for the immune system.

2 Oct 2012

Loyola launches experimental immune system therapy clinical trial for melanoma in the Midwest

Loyola University Medical Center has launched the first clinical trial in the Midwest of an experimental melanoma treatment that genetically engineers a patient's immune system to fight the deadly cancer.

2 Oct 2012

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of overall survival (OS) data from the trastuzumab emtansine Phase III trial, EMILIA.

2 Oct 2012

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).

1 Oct 2012

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Seattle Genetics, Inc., today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas.

1 Oct 2012

Active Biotech, Ipsen announce new data on biomarkers from tasquinimod Phase II study in CRPC

Active Biotech and Ipsen have presented a new set of data on biomarkers from the previously concluded tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific congress ESMO (European Society for Medical Oncology) held in Vienna September 28-October 2.

1 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

Drug Trial News

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Mexiletine improves patient-reported stiffness in nondystrophic myotonia

Penn researchers to begin Microbion's BisEDT gel Phase 2 trials in post-surgical orthopedic infections

Circassia commences ToleroMune phase 3 trial in cat allergen-induced rhinoconjunctivitis

Estrogen/progesterone treatment started soon after menopause appears safe and effective

Positive data from three Onconova Ex-RAD clinical trials on acute radiation syndrome

Merck announces data from MK-3102 Phase IIb trial on type 2 diabetes

Vitamin D3 intake does not reduce incidence or severity of upper respiratory tract infections

Mexiletine use improves stiffness in patients with nondystrophic myotonias

Boehringer Ingelheim, Lilly announce data from LY2605541 Phase II study on type 2 diabetes

Positive results from Noven’s LDMP Phase 3 clinical studies on menopausal VMS

Biomarkers can increase success rate of clinical trials for breast cancer drugs by almost 50%

Omega-3 fatty acid supplements could slow key biological process linked to aging

Novel therapy shows promise in treating multiple myeloma following stem cell transplants

Loyola launches experimental immune system therapy clinical trial for melanoma in the Midwest

OS data from ImmunoGen's trastuzumab emtansine Phase III trial on breast cancer

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Active Biotech, Ipsen announce new data on biomarkers from tasquinimod Phase II study in CRPC

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News